BULENT OZPOLAT to RNA, Small Interfering
This is a "connection" page, showing publications BULENT OZPOLAT has written about RNA, Small Interfering.
Connection Strength
2.640
-
Down-regulation of 5-HT1B and 5-HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. PLoS One. 2014; 9(9):e110067.
Score: 0.323
-
Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014 Feb; 66:110-6.
Score: 0.307
-
Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010 Jan; 267(1):44-53.
Score: 0.232
-
Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008 Jul; 4(5):669-79.
Score: 0.206
-
Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1. Breast Cancer. 2022 Nov; 29(6):1106-1120.
Score: 0.140
-
RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022 03; 182:114113.
Score: 0.134
-
Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2020 01; 80(1):65-73.
Score: 0.115
-
EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond). 2019 09; 14(17):2315-2338.
Score: 0.113
-
MicroRNA-based Targeted Therapeutics in Pancreatic Cancer. Anticancer Res. 2019 Feb; 39(2):529-532.
Score: 0.109
-
Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer. 2018 10; 124:31-39.
Score: 0.105
-
Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin ?1/ Src signaling in triple negative breast cancer cells. J Cancer Res Clin Oncol. 2018 Mar; 144(3):415-430.
Score: 0.101
-
Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer. Nanomedicine (Lond). 2017 Aug; 12(16):1961-1973.
Score: 0.098
-
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29; 87:108-19.
Score: 0.083
-
Elongation factor-2 kinase regulates TG2/?1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. J Cell Mol Med. 2014 Nov; 18(11):2235-51.
Score: 0.080
-
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57.
Score: 0.070
-
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
Score: 0.066
-
Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010 May; 9(5):1180-7.
Score: 0.059
-
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010 Apr; 6(3):322-9.
Score: 0.059
-
Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer. 2009 Jul 15; 125(2):264-75.
Score: 0.056
-
Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis. 2008 Jul; 13(7):915-28.
Score: 0.052
-
PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy. 2007 Sep-Oct; 3(5):480-3.
Score: 0.048
-
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan; 5(1):95-108.
Score: 0.047
-
Oligonucleotide-based theranostic nanoparticles in cancer therapy. Nanomedicine (Lond). 2016 05; 11(10):1287-308.
Score: 0.022
-
Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res. 2007 Mar; 5(3):241-9.
Score: 0.012